Having trouble accessing articles? Reset your cache.

BIO expects year-end drug pricing legislation

Congress is likely to enact drug pricing provisions as part of a year-end budget bill rather than as stand-alone legislation, BIO President and CEO Jim Greenwood said Monday. While there is unanimity on Capitol Hill about the need to make drugs more affordable, there are sharp divisions within and between Democrats and Republicans over the best way to tackle the issue.

Greenwood told reporters his prediction is based in part on recent discussions with staffers for Senate Majority Leader Mitch McConnell (R-Ky.).

Shoehorning drug pricing measures into a budget bill allows Senate and House leaders to forge deals behind closed doors, minimizing opportunities for stakeholders, or

Read the full 1047 word article

User Sign In

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers